Heron Therapeutics is committed to supporting programs and activities that inspire best-in-class patient care, medical and scientific education, and patient advocacy.
In alignment with our goals to develop best-in-class medicines for the management of cancer and pain, Heron is focused on initiatives related to the areas of oncology, supportive care oncology, postoperative pain management, and reducing opioid dependence.
Heron will review funding requests from healthcare- or science-related organizations for the following:
- Investigator-Initiated Trials
- Medical Educational Grants (including CME accredited programs)
- Charitable Contributions
As a general guidance for IITs, please note that Heron considers many factors which may include:
- Scientific and medical merit
- Relevant areas of research interest
Within the Acute Care Product Portfolio, Heron is interested in research studies where ZYNRELEF® (bupivacaine and meloxicam) would be used in conjunction with non-opioid multi-modal postoperative pain management strategies with a goal of reducing the use of opioids, especially in OB/GYN, general surgery, orthopedic, colorectal, and plastics.
As general guidance for grant requests, please note that Heron considers many factors which may include:
- Promotes excellence in patient care
- Meets CME guidelines related to content, venue, and dissemination as applicable
- Is conducive to an effective and efficient meeting format
- Educates the broadest target audience at an appropriate and reasonable cost
Heron is committed to complying with all applicable transparency reporting and disclosure obligations, including those relating to state and federal regulations and as stipulated by the National Physician Payment Transparency Program. At this time, Heron can only accept applications from institutions located within the United States.
To complete a form and submit a proposal for an IIT click here.
To complete a form and submit a proposal for a grant click here.
To complete a form and submit a proposal for a sponsorship or contribution click here.
Please submit any proposals at least 60 days in advance of a program or event for which funding is being requested.
SUSTOL® (granisetron) extended-release injection is a serotonin-3 (5-HT3) receptor antagonist that is approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
CINVANTI® (aprepitant) injectable emulsion, for intravenous use is a substance P/neurokinin-1 (NK1) receptor antagonist that is approved by the FDA and is indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen; and nausea and vomiting associated with the initial and repeat courses of MEC as a 3-day regimen.
In February 2019, the FDA approved the administration of CINVANTI as a 2-minute IV injection (push), providing an alternative to 30-minute IV infusion. CINVANTI is now the only IV NK1 RA that offers the operational flexibility of a 2-minute IV push.
In July 2020, we initiated a Phase 2 clinical study evaluating CINVANTI in early hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Limitations of Use: CINVANTI has not been studied for treatment of established nausea and vomiting.
ZYNRELEF® (bupivacaine and meloxicam) extended-release solution is approved in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
ZYNRELEF is the first and only extended-release dual-acting local anesthetic™ (DALA™) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery. ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is formulated in Heron’s proprietary controlled-diffusion Biochronomer® polymer for consistently regulated delivery of bupivacaine and meloxicam. ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication. In April 2021, Heron responded to a list of questions received from Health Canada and we anticipate up to a 300-day review period following screening of the response. In September 2020, the European Commission (EC) granted a marketing authorization for ZYNRELEF for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. As of January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the European Union and European Economic Area and the United Kingdom.
Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
Sign-Up for Email Updates
Receive news and updates on Heron’s latest innovations.